
Conference Coverage
Latest News

Capsulotomy diameter as a potential refractive planning variable

A first for advanced RP: Bakall on the MOGENRY BLA acceptance and what an in-office option would mean

Bausch + Lomb's SeeLyra femtosecond laser earns European CE mark

The pediatric blind spot: What ocular gene therapy trials still aren’t telling clinicians about children

MacTel and neovascular conversion: Majda Hadziahmetovic, MD, on early warning signs

Shorts










Digital Edition








Podcasts
Continuing Medical Education
All News

AMA resolution backs classifying myopia as a disease, aiming to expand insurance coverage for pediatric myopia control treatments.

In patients reporting chronic ocular pain, dry eye may not be the entire diagnosis.

Polish investigators showed that various modalities can quantify ocular changes in attention deficit/hyperactivity disorder.

Mingo Botín, MD, PhD, discusses ESCRS 2026 data on an EDOF IOL in post-LASIK eyes vs non-LASIK controls.

The 44th Congress of the ESCRS kicked off at ExCeL London with iNovation Day and the Opening Ceremony, setting the stage for a five-day programme.

Opus Genetics announced positive 3- and 6-month results OPGx-BEST1 in BEST1-related retinal diseases.

A JAMA Ophthalmology Clinical Trial of the Year enrolled 1421 eyes across 28 sites, with NEI-funded follow-up extending the findings to 5 years.

Handheld IC1000 pairs rebound tonometry with camera-guided alignment

The FDA accepted Nanoscope's BLA for MOGENRY (sonpiretigene isteparvovec, MC-010), a gene therapy for retinitis pigmentosa with severe vision loss, supported by RESTORE trial data showing sustained BCVA improvement.

Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.

Dante Pieramici, MD, discusses the phase 3 COMO and CAPRI trials of EYP-1901 in diabetic macular edema and what 6-month dosing could mean for treatment burden.

New research covers a 3D OCT foundation model, an OCTA biomarker review and offline smartphone screening for three retinal diseases.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Study authors discuss fishing-related eye injury patterns, pediatric risk, and prevention strategies drawn from other sports.

A gamified program may speed the brain’s adjustment, new data suggest.





















